Where is CVRx located?

CVRx is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota.

How many employees does CVRx have?

As of Jun 30, 2026, the latest employee count at CVRx is 252.

Is CVRx a funded company?

CVRx is a funded company, having raised a total of $394M across 10 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of CVRx?

CVRx's latest funding was a $***** Series F round on Jul 07, 2020, with participation from 8 investors.

What is the annual revenue of CVRx?

Annual revenue of CVRx is between $50M and $100M as on Dec 31, 2025

Where does CVRx rank among its competitors?

CVRx ranks 1st amongst 99 active competitors, of which 58 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was FineHeart, which secured $40.8M in Jan, 2026.

Who are the top competitors of CVRx?

CVRx's top competitors include Impulse Dynamics, CorWave and Element Science. Among them, FineHeart secured the most recent funding round in January, 2026.

CVRx - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the body's cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.

Website: cvrx.com
Social
Registered Address: Minneapolis, Minnesota

Key Metrics

Founded Year

2001

Location

Minneapolis, United States

Stage

Public

Total Funding

$394M in 10 rounds

Latest Funding Round

Series F, Jul 07, 2020, $*****

Investors

Johnson & Johnson Innovation – JJDC & 21 more

Ranked

1^st among 99 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

252 as on Jun 30, 2026

Similar Companies

Impulse Dynamics & 125 more

Exit Details

Public

View CVRx's full profile

CVRx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CVRX, INC. CIN: 411983744 , United States, Active	Dec 31, 2000	$50M - $100M (As on Dec 31, 2025)	194 (As on Dec 31, 2024)	-

CVRx got listed on Jun 30, 2021.

Click here to take a look at CVRx's IPO in detail

CVRx has raised a total funding of $394M over 10 rounds. Its latest funding round was a Series F round on Jul 07, 2020 for $*****. 8 investors participated in its latest round. CVRx has 22 institutional investors.

Here is the list of recent funding rounds of CVRx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 07, 2020	4685596	Series F	2305538	3805712	2457000	7044198
May 31, 2019	2639384	Series F	8070255	2033105	2868379	New Enterprise Associates & 4 more
Aug 09, 2016	3611499	Conventional Debt	6339452	2761160	7348806	Oxford Finance

Access funding benchmarks and valuations. Sign up today!

View details of CVRx's funding rounds and investors

The founders of CVRx is Robert Kieval.

Here are the details of CVRx's key team members:

Robert Kieval: Former Founder of CVRx.

View details of CVRx's Founder profiles and Board Members

CVRx's employee count trend

CVRx has 252 employees as of Jun 26. Here is CVRx's employee count trend over the years:

Uncover CVRx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CVRx include Impulse Dynamics, CorWave and Element Science. Here is the list of Top 10 competitors of CVRx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CVRx 2001, Minneapolis (United States), Public	Developer of implantable technology for hypertension and heart failure	$394M	Gilde Healthcare, Piper Jaffray & 20 others	68/100
2nd	Impulse Dynamics 1998, Marlton (United States), Series F	Provider of implantable device for treatment of chronic heart failure	$685M	Perceptive Advisors, Amzak Health & 16 others	64/100
3rd	CorWave 2011, Paris (France), Series C	Developer of implantable blood pumps for the treatment of heart failure	$127M	Novo Holdings, Sofinnova Partners & 11 others	61/100
4th	Element Science 2013, San Francisco (United States), Series C	Wearable therapeutic device for treating sudden cardiac arrest	$193M	Deerfield, Qiming & 4 others	61/100
5th	SynCardia 2001, Tucson (United States), Public	Artificial heart	$72M	Athyrium Capital Management, SWK Holdings ... & 5 others	60/100
6th	Restore Medical 2016, Tel Aviv (Israel), Series B	Catheter-delivered implant for treatment of congestive heart failure	$32M	European Innovation Council, Pitango & 3 others	58/100
7th	InterShunt Technologies 2015, Louisiana (United States), Series B	Developer of cardiac catheter for the treatment of cardiac diseases	$26.6M	Solas BioVentures, Gener8tor & 6 others	57/100
8th	FineHeart 2010, Pessac (France), Series C	Developer of an implantable cardiovascular device for treating heart failures	$51.9M	Verve Ventures, Broadview Ventures & 16 others	57/100
9th	Corvia Medical 2009, Tewksbury (United States), Acquired	Developer of transcatheterally shunt for treating diastolic heart failure disease	$160M	Edwards Lifesciences, Accelmed & 4 others	57/100
10th	Reprieve Cardiovascular 2018, Milford (United States), Series B	Developer of decongestion management solution for acute decompensated heart failure patients	$150M	Deerfield, Arboretum Ventures & 8 others	56/100